blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3867276

EP3867276 - ABITUZUMAB FOR THE TREATMENT OF COLORECTAL CANCER [Right-click to bookmark this link]
StatusRequest for examination was made
Status updated on  23.07.2021
Database last updated on 30.10.2024
FormerThe international publication has been made
Status updated on  24.04.2020
Formerunknown
Status updated on  13.12.2019
Most recent event   Tooltip13.09.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Merck Patent GmbH
Frankfurter Strasse 250
64293 Darmstadt / DE
[2021/34]
Inventor(s)01 / MASSIMINI, Giorgio
Wilhelm-Leuschner-Strasse 3
64293 Darmstadt / DE
02 / CELIK, Ilhan
Stuckertstrasse 8
64673 Zwingenberg / DE
03 / STRAUB, Josef
Hauptstrasse 23
64342 Seeheim-jugenheim / DE
04 / BRUNS, Rolf
Claudiusweg 25
64285 Darmstadt / DE
 [2021/34]
Representative(s)Merck Patent Association
Merck Patent GmbH
64271 Darmstadt / DE
[N/P]
Application number, filing date19813413.218.10.2019
[2021/34]
WO2019EP78327
Priority number, dateUS201862748114P19.10.2018         Original published format: US 201862748114 P
[2021/34]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2020079209
Date:23.04.2020
Language:EN
[2020/17]
Type: A1 Application with search report 
No.:EP3867276
Date:25.08.2021
Language:EN
The application published by WIPO in one of the EPO official languages on 23.04.2020 takes the place of the publication of the European patent application.
[2021/34]
Search report(s)International search report - published on:EP23.04.2020
ClassificationIPC:C07K16/28, A61K39/395, A61K31/4745, A61P35/00, A61P35/04
[2021/34]
CPC:
C07K16/2848 (EP,US); A61K39/39558 (US); A61K31/44 (US);
A61K31/4745 (EP,US); A61K31/513 (US); A61K31/519 (US);
A61K31/7072 (US); A61K33/243 (US); A61K38/179 (US);
A61K39/3955 (EP); A61K45/06 (EP); A61P35/00 (EP,US);
A61P35/04 (EP); C07K16/22 (US); C07K16/2863 (EP,US);
A61K2039/505 (EP,US); A61K2039/507 (EP,US); A61K2039/545 (US);
C07K2317/24 (EP); C07K2317/76 (US) (-)
C-Set:
A61K31/4745, A61K2300/00 (EP);
A61K39/3955, A61K2300/00 (EP)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2021/34]
TitleGerman:ABITUZUMAB ZUR BEHANDLUNG VON KOLOREKTALKREBS[2021/34]
English:ABITUZUMAB FOR THE TREATMENT OF COLORECTAL CANCER[2021/34]
French:ABITUZUMAB POUR LE TRAITEMENT DU CANCER COLORECTAL[2021/34]
Entry into regional phase19.04.2021National basic fee paid 
19.04.2021Designation fee(s) paid 
19.04.2021Examination fee paid 
Examination procedure19.04.2021Examination requested  [2021/34]
19.04.2021Date on which the examining division has become responsible
06.12.2021Amendment by applicant (claims and/or description)
Fees paidRenewal fee
29.09.2021Renewal fee patent year 03
15.09.2022Renewal fee patent year 04
13.09.2023Renewal fee patent year 05
12.09.2024Renewal fee patent year 06
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Cited inInternational search[XI]WO2016041614  (MERCK PATENT GMBH [DE]) [X] 1,4-6,8,14-20,23-36,41,43-46,50,52 * example 1 * [I] 2,3,7,9-13,21,22,37-40,42,47-49,51,53,54,56,57,59-64;
 [XDI]  - E ÉLEZ ET AL, "Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.", ANNALS OF ONCOLOGY, (20141015), vol. 26, no. 1, doi:10.1093/annonc/mdu474, pages 132 - 140, XP055665322 [XD] 1,4-6,8,14-20,23-36,41,43-46,50,52 * figure 3 * * table 3 * [I] 2,3,7,9-13,21,22,37-40,42,47-49,51,53,54,56,57,59-64

DOI:   http://dx.doi.org/10.1093/annonc/mdu474
 [XI]  - Josef Straub ET AL, "Abstract 582: Prognostic and predictive value of plasma protein signatures in a phase I/II trial of abituzumab combined with cetuximab/irinotecan in second-line KRAS wild-type metastatic colorectal cancer (mCRC)", Cancer Research, doi:10.1158/1538-7445.AM2015-582, (20150801), URL: https://cancerres.aacrjournals.org/content/75/15_Supplement/582, (20200205), XP055665310 [X] 1,4-6,8,14-20,23-36,41,43-46,50,52 * abstract * [I] 2,3,7,9-13,21,22,37-40,42,47-49,51,53,54,56,57,59-64

DOI:   http://dx.doi.org/10.1158/1538-7445.AM2015-582
 [AD]  - D ARNOLD ET AL, "Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials", ANNALS OF ONCOLOGY, (20170801), vol. 28, no. 8, doi:10.1093/annonc/mdx175, pages 1713 - 1729, XP055665587 [AD] 1-64 * page 1727, paragraph l *

DOI:   http://dx.doi.org/10.1093/annonc/mdx175
 [A]  - J GRAS, "Abituzumab", DRUGS OF THE FUTURE, (20150201), vol. 40, no. 2, doi:10.1358/dof.2015.40.2.2264075, pages 97 - 100, XP055665319 [A] 1-64

DOI:   http://dx.doi.org/10.1358/dof.2015.40.2.2264075
 [AD]  - BATES RICHARD C ET AL, "Transcriptional activation of integrin beta6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma", JOURNAL OF CLINICAL INVESTIGATION, B M J GROUP, GB, (20050201), vol. 115, no. 2, doi:10.1172/JCI23183, ISSN 0021-9738, pages 339 - 347, XP009170831 [AD] 1-64

DOI:   http://dx.doi.org/10.1172/JCI23183
 [T]  - R Laeufle ET AL, "487P Patient selection for targeting integrin with abituzumab in patients with metastatic colorectal cancer (mCRC): A retrospective analysis of the randomized phase I/II Poseidon study", Annals of Oncology, doi:10.1093/annonc/mdy281.035, (20181023), URL: https://academic.oup.com/annonc/article/29/suppl_8/mdy281.035/5141435, (20200205), XP055665537

DOI:   http://dx.doi.org/10.1093/annonc/mdy281.035
by applicantEP0531472
 EP0719859
 US5985278
 WO03053465
 WO2005077414
 WO2009010290
    - MATIAS RIIHIMAKIAKSELI HEMMINKIJAN SUNDQUISTKARI HEMMINKI, Scientific Reports, vol. 6, page 29765
    - BISANZ et al., Molecular Therapy, (20050000), vol. 12, pages 634 - 643
    - MCCABE et al., Oncogene, (20070000), vol. 26, pages 6238 - 6243
    - BATES RCBELLOVIN DIBROWN C et al., "Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma", The Journal of Clinical Investigation, (20050000), vol. 115, no. 2, doi:10.1172/JCI23183, pages 339 - 347, XP009170831

DOI:   http://dx.doi.org/10.1172/JCI23183
    - YANG GYGUO SDONG CY et al., "Integrin av36 sustains and promotes tumor invasive growth in colon cancer progression", World Journal of Gastroenterol., (20150000), vol. 21, no. 24, pages 7457 - 7467
    - ARNAOUT MAGOODMAN SLXIONG JP, "Structure and mechanics of integrin-based cell adhesion", Curr Opin Cell Biol., (20070000), vol. 19, no. 5, doi:10.1016/j.ceb.2007.08.002, pages 495 - 507, XP022323046

DOI:   http://dx.doi.org/10.1016/j.ceb.2007.08.002
    - GOEL HLLANGUINO LR, "Integrin signaling in cancer", Cancer Treat Res., (20040000), vol. 119, page 15 31
    - NEMETH JANAKADA MTTRIKHA M et al., "Alpha-v integrins as therapeutic targets in oncology", Cancer Invest., (20070000), vol. 25, no. 7, pages 632 - 646
    - ELEZ EKOCAKOVA IHOHLER T et al., "Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase l/ll POSEIDON trial", Annals of Oncology, (20150000), vol. 26, pages 132 - 140
    - BEVER KMLE DT, "An Expanding Role for Immunotherapy in Colorectal Cancers", Journal of the National Comprehensive Cancer Network, (20170000), vol. 15, no. 3, pages 401 - 410
    - LEE MSMENTER DGKOPETS S, "Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes", Journal of the National Comprehensive Cancer Network, (20170000), vol. 15, no. 3, pages 411 - 419
    - LEE B et al., "Left versus right sided colorectal cancer: Teasing out drivers of disparity in outcomes in metastatic disease", Journal of Clinical Oncology, (20170000), vol. 35, no. 4, pages 682 - 682
    - MICHAL MIKMACIEJ BERUTLUKASZ DZIKIRADZISLAW TRZCINSKIADAM DZIKI, Arch Med Sci, (20170000), vol. 13, no. 1, pages 157 - 162
    - SIMON L. GOODMANHANS JUERGEN GROTECLAUDIA WILM, Biology Open, (20120000), vol. 1, pages 329 - 340
    - GOODMAN SLGROTE HJWILM C, "Matched rabbit monoclonal antibodies against av-series integrins reveal a novel av(33-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors", Biol Open, (20120000), vol. 1, doi:10.1242/bio.2012364, pages 329 - 340, XP055291519

DOI:   http://dx.doi.org/10.1242/bio.2012364
    - PIRKER RPEREIRA JRVON PAWEL J et al., "EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cell lung cancer: analysis of data from the phase 3 FLEX study", Lancet Oncol, (20120000), vol. 13, pages 33 - 42
    - J HANJM VAN KRIEKENETIENNE ROULEAUMARJOLIJN J. L. LIGTENBERGNICOLA NORMANNOSCOTT D. PATTERSONANDREAS JUNG, Virchows Arch, (20160000), vol. 468, pages 383 - 396
    - N. NORMANNOR. ESPOSITO ABATEM. LAMBIASEL. FORGIONEC. CARDONEA. LANNACCONEA. SACCOA. M. RACHIGLIOE. MARTINELLID. RIZZI, Annals of Oncology, (20180000), vol. 29, pages 112 - 118
    - J. GRASSELLI et al., Annals of Oncology, (20170000), vol. 28, pages 1294 - 1301
    - RAFAEL G. AMADOMICHAEL WOLFMARC PEETERSERIC VAN CUTSEMSALVATORE SIENADANIEL J. FREEMANTODD JUANROBERT SIKORSKISID SUGGSROBERT RADINSKY, Clin Oncol, (20080000), vol. 26, pages 1626 - 1634
    - ARNOLD DCUTSEM E. VCERVANTES A et al., "Metastatic Colorectal Cancer: ESMO Clinical Practice Guidelines", Annals of Oncology, (20140000), vol. 25, no. 3, pages iii1 - iii9
    - MCCARTY JR KSMILLER LSCOX EBKONRATH JMCCARTY SR KS, "Estrogen receptor analyses: Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies", Arch Pathol Lab Med, (19850000), vol. 109, pages 716 - 721
    - MITJANS et al., J.Cell Sci., (19950000), vol. 108, page 2825
    - WAGNER, Biomaterials, (20100000), vol. 8, pages 2388 - 98
    - VAN CUTSEM ECERVANTES ANORDLINGER B et al., "Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, (20140000), vol. 25, no. 3, pages iii1 - iii9
    - CIOMBOR KKBERLIN J, "Targeting metastatic colorectal cancer— present and emerging treatment options", Pharmgenomics Pers Med, (20140000), vol. 7, pages 137 - 144
    - GOODMAN SLPICARD M, "Integrins as therapeutic targets", Trends Pharmacol Sci, (20120000), vol. 33, doi:10.1016/j.tips.2012.04.002, pages 405 - 412, XP028495741

DOI:   http://dx.doi.org/10.1016/j.tips.2012.04.002
    - NEMETH JANAKADA MTTRIKHA M et al., "Alpha-v integrins as therapeutic targets in oncology", Cancer Invest, (20070000), vol. 25, pages 632 - 646
    - AGREZ MVBATES RCMITCHELL D et al., "Multiplicity of fibronectin-binding alpha V integrin receptors in colorectal cancer", Br J Cancer, (19960000), vol. 73, pages 887 - 892
    - BATES RCBELLOVIN DIBROWN C et al., "Transcriptional activation of integrin β6 during the epithelial-mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma", J Clin Invest, (20050000), vol. 115, doi:10.1172/JCI23183, pages 339 - 347, XP009170831

DOI:   http://dx.doi.org/10.1172/JCI23183
    - MITJANS FSANDER DADAN J et al., "An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice", J Cell Sci, (19950000), vol. 108, pages 2825 - 2838, XP002615476
    - UHL WZUHLSDORF MKOERNICKE T et al., "Safety, tolerability, and pharmacokinetics of the novel alphav-integrin antibody EMD 525797 (DI17E6) in healthy subjects after ascending single intravenous doses", Invest New Drugs, (20140000), vol. 32, pages 347 - 354
    - WIRTH MHEIDENREICH AGSCHWEND JE et al., "A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting alphav integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy", Eur Urol, (20140000), vol. 65, doi:10.1016/j.eururo.2013.05.051, pages 897 - 904, XP055338878

DOI:   http://dx.doi.org/10.1016/j.eururo.2013.05.051
    - ELEZ EKOCAKOVA IHOHLER T et al., "Phase I study of EMD 525797 (DI17E6), an antibody targeting av(3 integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer", J Clin Oncol, (20120000), vol. 30, page 3539
    - THERASSE PARBUCK SGEISENHAUER EA et al., "New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada", J Natl Cancer Inst, (20000000), vol. 92, pages 205 - 216
    - BATES RC, "Colorectal cancer progression: integrin alphavbeta6 and the epithelial mesenchymal transition (EMT", Cell Cycle, (20050000), vol. 4, doi:10.4161/cc.4.10.2053, pages 1350 - 1352, XP009170854

DOI:   http://dx.doi.org/10.4161/cc.4.10.2053
    - TRAVIS MASHEPPARD D, "TGF-beta activation and function in immunity", Annu Rev Immunol, (20140000), vol. 32, pages 51 - 82
    - CIOMBOR KKBERLIN J, "Targeting metastatic colorectal cancer—present and emerging treatment options", Pharmgenomics Pers Med, (20140000), vol. 7, pages 137 - 144
    - ELEZ EKOCAKOVA IHOHLER T et al., "Phase I study of EMD 525797 (D!17E6), an antibody targeting av3 integrins, in combination with cetuximab and irinotecan, as a second-line treatment for patients with k-ras wild-type metastatic colorectal cancer", J Clin Oncol, (20120000), vol. 30, page 3539
    - PIRKER RPEREIRA JRVON PAWEL J et al., "EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small cel lung cancer: analysis of data from the phase 3 FLEX study", Lancet Oncol, (20120000), vol. 13, pages 33 - 42
    - "New guidelines to evaluate the response to treatment in solid tumors", THERASSE PARBUCK SGEISENHAUER EA et al., J Natl Cancer Inst, European Organization for Research and Treatment of Cancer, (20000000), vol. 92, pages 205 - 216
    - BATES RC et al., J Clin Invest., (20050000), vol. 115, no. 2, pages 339 - 347
    - NIU Z et al., Cell Biosci, (20140000), vol. 4, page 23
    - YANG GY et al., World J Gastroenterol., (20150000), vol. 21, no. 24, pages 7457 - 7467
    - ELEZ E et al., Ann Oncol., (20150000), vol. 26, pages 132 - 140
    - ARNOLD D et al., Ann Oncol., (20170000), vol. 28, pages 1713 - 1729
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.